TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an announcement.
ResMed Inc has reported a change in beneficial ownership as Director Christopher DelOrefice acquired 1,073 shares of common stock through Restricted Stock Units (RSUs) that vest by November 2026 or at the next annual stockholders’ meeting. This transaction reflects the company’s ongoing commitment to align its leadership’s interests with shareholder value, potentially impacting the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$42.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc operates in the healthcare industry, primarily focusing on the development and manufacturing of products for the treatment of sleep disorders, such as sleep apnea, and other respiratory conditions. The company is known for its innovative solutions in sleep and respiratory care, catering to a global market with a range of devices and cloud-connected solutions.
Average Trading Volume: 1,214,271
Technical Sentiment Signal: Buy
Current Market Cap: A$56.69B
Learn more about RMD stock on TipRanks’ Stock Analysis page.